The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Trumenba (Meningococcal Group B Vaccine), from Pfizer,...
Pfizer announced positive topline results of two Phase III studies of Trumenba (meningococcal group B vaccine). One study included approximately...
Pfizer announced that the European Commission (EC) has approved Trumenba (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal...
Pfizer Inc. announced results of two Phase III studies demonstrating the immunogenicity of Trumenba (Meningococcal Group B Vaccine) against invasive...
Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Trumenba (bivalent rLP2086) is a vaccine licensed for the prevention of meningococcal meningitis disease caused by Neisseria meningitidis serogroup B (NmB) in individuals 10-25 years of age in the USA.
Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. See section 5.1 for information on the immune response against specific serogroup B strains. The use of this vaccine should be in accordance with official recommendations.
Two phase III trials reported in NEJM for Trumenba showing a protective immune response against diverse meningococcal group B (MenB) strains.
Background: In February 2015, two unlinked culture-confirmed cases of Neisseria meningitidis serogroup B (MenB) disease occurred at a local college in Rhode Island ("college X") within 3 days.
Neisseria meningitidis is a common cause of bacterial meningitis, often leading to permanent sequelae or death. N. meningitidis is classified into serogroups based on the composition of the bacterial capsular polysaccharide...